Evidence map›Paper›PMID 32368097›Full record

ArticleOncoTargets and therapy2020

Effects of miR-330-3p on Invasion, Migration and EMT of Gastric Cancer Cells by Targeting PRRX1-Mediated Wnt/β-Catenin Signaling Pathway.

Bingqiang Ma, Jianxun Ma, Yili Yang, Xueyuan He, Xinmin Pan, Zhan Wang, Yaowen Qian

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Wnt/β-catenin-driven EMT regulation in human cancers.Cellular and molecular life sciences : CMLS · 2024
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. International journal of genomics · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Bingqiang Ma *Department of General Surgery, Cancer Center, Key Laboratory for Diagnosis and Treatment of Gastrointestinal Cancer, Gansu Provincial Hospital, Lanzhou, Gansu Province, People's Republic of China.
Jianxun Ma *Department of General Surgery, Cancer Center, Key Laboratory for Diagnosis and Treatment of Gastrointestinal Cancer, Gansu Provincial Hospital, Lanzhou, Gansu Province, People's Republic of China.
Yili YangDepartment of General Surgery, Cancer Center, Key Laboratory for Diagnosis and Treatment of Gastrointestinal Cancer, Gansu Provincial Hospital, Lanzhou, Gansu Province, People's Republic of China.
Xueyuan HeDepartment of General Surgery, Cancer Center, Key Laboratory for Diagnosis and Treatment of Gastrointestinal Cancer, Gansu Provincial Hospital, Lanzhou, Gansu Province, People's Republic of China.
Xinmin PanDepartment of General Surgery, Cancer Center, Key Laboratory for Diagnosis and Treatment of Gastrointestinal Cancer, Gansu Provincial Hospital, Lanzhou, Gansu Province, People's Republic of China.
Zhan WangDepartment of General Surgery, Cancer Center, Key Laboratory for Diagnosis and Treatment of Gastrointestinal Cancer, Gansu Provincial Hospital, Lanzhou, Gansu Province, People's Republic of China.
Yaowen QianDepartment of General Surgery, Cancer Center, Key Laboratory for Diagnosis and Treatment of Gastrointestinal Cancer, Gansu Provincial Hospital, Lanzhou, Gansu Province, People's Republic of China.ORCID 0000-0002-5167-5978
Gansu Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundmiRNA, as a biological marker, had more and more attention in recent years due to the important role it plays in cancer. Currently, there are extensive studies on miRNAs, among which miR-330-3p is reported to be implicated in the pathophysiological processes of various cancers. However, little progress has been made in the mechanism of miR-330-3p in gastric cancer.

objectiveTo explore the expression and relevant mechanism of miR-330-3p and PRRX1 in gastric cancer (GC).

methodsForty-five GC patients (study group), from whom paired GC and paracancerous tissues were collected, and another 45 healthy subjects (control group) who underwent physical examination during the same period were enrolled. In addition, GC cells and human gastric mucosa cells were purchased, and miR-330-3p-mimics, miR-330-3p-inhibitor, miR-NC, si-PRRX1, and sh-PRRX1 were transfected into MKN45, SGC7901 cell. QRT-PCR was employed to assess the miR-330-3p and PRRX1 expressions in the samples, and the cell expressions of PRRX1, GSK-3β, p-GSK-3β, β-catenin, p-β-catenin, cyclin D1, N-cadherin, E-cadherin and vimentin were evaluated by Western blot (WB). MTT, Transwell and wound-healing experiments were adopted to detect cell proliferation, invasion and migration.

resultsMiR-330-3p was under-expressed, while PRRX1 was highly expressed in the serum of patients, both of which had an area under the curve (AUC) of more than 0.9. MiR-330-3p and PRRX1 were associated with tumor diameter, TNM staging, lymph node metastasis and differentiation of GC patients. Overexpression of miR-330-3p and inhibition of PRRX1 expression could suppress epithelial-mesenchymal transition (EMT), proliferation, invasion and apoptosis of cells. What is more, WB assay showed that overexpressed miR-330-3p and inhibited PRRX1 could inhibit the expression levels of p-GSK-3β, β-catenin, cyclin D1, N-cadherin and vimentin proteins, while elevating GSK-3β, p-β-catenin and E-cadherin protein expressions. Dual-luciferase reporter assay confirmed that there was a targeting relation between miR-330-3p and PRRX1. Furthermore, rescue experiments revealed that the cell proliferation, invasion, migration did not differ significantly between co-transfected miR-330-3p-mimics+sh-PRRX1, miR-330-3p-inhibitor+si-PRRX1 groups of MKN45 and SGC7901 and the miR-NC group (without transfected sequences).

conclusionOverexpressed miR-330-3p can promote cell EMT, proliferation, invasion and apoptosis through inhibiting PRRX1-mediated Wnt/β-catenin signaling pathway, which is expected to be a potential therapeutic target for GC.

Indexed as

biological functionGCmiR-330-3pPRRX1Wnt/β-catenin signaling pathway

Identifiers

PMID32368097
PMCPMC7183782
OpenAlexW3019519586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.